The TANGO study demonstrated non-inferior virologic efficacy (HIV-1 RNA ?50 c/mL by Snapshot algorithm) of switching to a 2DR of DTG/3TC vs continuing 3-or 4-drug TAF-based regimens (TBR) in virologically suppressed adults with HIV-1 at 144 weeks. Abbott RealTime HIV-1 assay measures viral load (VL) from 40 to 10,000,000 c/mL and provides qualitative target detected (TD) or target not detected (TND) outcomes for VL <40 c/mL. VL <50 c/mL has unknown clinical influence, and low-level viremia may depend on pre-treatment VL and proviral DNA load set-points. Previous assessment of low-level viremia using TND/TD measures showed that more participants on DTG/3TC than those continuing TBR had TND at all visits through Week 96. We present here longer-term HIV-1 RNA data with TD/TND and elevated VL through Week 144 (WK144).
Proportions of participants with VL <40 c/mL and TND status were analyzed by visit (Snapshot) through WK144. Participants' TD/TND status over time, overall and by baseline VL classifications, was assessed. The frequency of elevated VL (VL ?50 c/mL) categories including 'blips' was also determined.
At WK144, similar proportions of participants had TND in the DTG/3TC and TBR arms (76% [279/369] vs 72% [267/372], respectively; adjusted difference using Cochran-Mantel-Haenszel method, 3.9%; 95% Cl: ?2.5, 10.2 by Snapshot) and proportions were also similar at each visit. Across baseline VL categories, proportions with TND at all visits through WK144 were 33% (123/369) in DTG/3TC arm vs 27% (101/372) in TBR arm (Table). More participants with TND at baseline had post-baseline TND at all visits compared with participants with higher baseline VL categories. The occurrence of elevated VL events remained low and similar across arms through WK144: 8% (28/369) in DTG/3TC arm vs 11% (42/372) in TBR arm. The most frequently observed VL rebounds were ‘blips’ with 5% in DTG/3TC arm and 7% in TBR arm. None of the 7 participants (4 on DTG/3TC vs 3 on TBR) with archived M184V/I experienced an elevated VL event through WK144.
The proportions of participants with VL <40 c/mL and TND by visit were high and comparable between treatment arms. Similar proportions of participants across both arms maintained post-baseline TND at all available visits through WK144 and >90% of participants with TND at baseline never had a VL ?40 c/mL. These long-term virology data continue to demonstrate the potency and durability of DTG/3TC compared to 3DR in maintaining viral suppression